- This event has passed.
CRDN Companies Forum Meeting
January 18 @ 10:00 am - 12:00 pmFree
In this session, a representative from the National Institute for Health and Care Excellence (NICE) will lead us through the Innovative Medicines Fund (IMF) in relation to rare diseases.
Thomas Strong: HTA Adviser – Managed Access (Cancer Drugs Fund) at NICE. Thomas will give a presentation on the IMF with a particular focus on the opportunities and potential impact for rare diseases. He will explore the eight guiding principles of the IMF and some of the background to these. Thomas will be joined by Sheela Uphadayaya, Rare Disease and Rapid C-19 Strategic Adviser at NICE, during the open discussion. Shella has joined us in previous meetings and always offers a thought-provoking session with clear guidance and interesting examples of good practice.
Much of the meeting will be devoted to vibrant discussion, so bring along questions from colleagues and your thoughts from the presentation. This session is very much an opportunity to clarify any uncertainties, debunk any myths and offer your views and opinion on the proposals as part of the IMF consultation. We will close the discussion with a live poll to gather your views on the consultation questions below.
We live in hope of holding in-person Forum events again later in 2022 Until then, we’ll strive to retain the spirit of the Companies Forum with an open and informal atmosphere encouraging challenge and debate. A reminder that Companies Forum operates under the Chatham House Rules, and we anonymise comments in the shared minutes. We hope that you’ll gain much insight from the meeting and can realise the potential of this new funding pathway for accelerating treatments for rare diseases.
10:00 – 10:10 Welcome and introductions
10:10 – 10:50 Speaker – Thomas Strong, NICE
10:50 – 11:40 Roundtable discussion
11:40 – 11:50 Live polling
11:50 – 12:00 Summing up and close